[Potential therapeutic implications of EGF R/PDGF R signalling pathways in bone metastases of prostate cancer].
The finding that EGF receptor (Epidermal Growth Factor Receptor) and PDGF receptor (Platelet-Derived Growth Factor Receptor) are involved in bone metastases opens up new therapeutic prospects. This new approach should allow the development of new therapeutic agents: EGF R/HER2 inhibitors and PDGF R antagonists.
Paule
Bernard
B
Service d'Urologie, Hôpital Henri Mondor, Créteil, France. bepaule@wanadoo.fr
D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000209:etiology* / Q000473:pathology*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction
D066246:ErbB Receptors; D017479:Receptors, Platelet-Derived Growth Factor